Spironolactone (Aldactone) — Complete UK Prescribing Guide

Basic Aldactone Information

• INN (International Nonproprietary Name): Spironolactone.
• Brand Names Available In United Kingdom: Aldactone and generic spironolactone (25 mg, 50 mg, 100 mg tablets); oral suspension formulations are available in some markets.
• ATC Code: C03DA01.
• Forms & Dosages: Tablets 25 mg, 50 mg, 100 mg; Oral suspension 25 mg/5 ml.
• Manufacturers In United Kingdom: Not specified.
• Registration Status In United Kingdom: Not specified.
• OTC / Rx Classification: Prescription-only (Rx) in major regulatory regions.

Key Findings From Recent Trials

Major 2022–2025 Studies

Which recent trials matter to clinicians and patients?

Randomised controlled trials and pooled meta-analyses from 2022 to 2025 examined spironolactone in heart failure and resistant hypertension cohorts.

High-quality analyses re‑affirmed a role for spironolactone as an add‑on in HFrEF and in resistant hypertension management.

Main Outcomes

What clinical benefits were observed?

Trials showed modest additional reductions in hospital admissions for heart failure when spironolactone was added to guideline‑directed medical therapy for HFrEF.

In resistant hypertension cohorts, spironolactone provided the largest reduction in ambulatory blood pressure compared with placebo or alternative potassium‑sparing diuretics.

These effects mirror legacy data such as RALES but now reflect contemporary background therapy.

Safety Observations

Who is at highest risk of harm?

Safety reports highlighted hyperkalaemia as the principal concern, particularly in patients with reduced eGFR, concurrent ACE inhibitor or ARB therapy, and older age.

Trials emphasised early and frequent monitoring of potassium and creatinine after initiation or dose changes.

Dermatology RCTs in women with hormonal acne supported efficacy at 50–100 mg/day but reinforced contraception counselling because of teratogenicity concerns extrapolated from animal studies.

European post‑marketing surveillance continued to list gynecomastia and menstrual irregularities as leading adverse events.

Clinical Mechanism Of Action

Layman’s Explanation

How does spironolactone work in plain terms?

Spironolactone is a potassium‑sparing diuretic that lowers fluid overload and blood pressure by blocking the action of aldosterone.

That helps the body get rid of sodium and water while keeping potassium, which reduces swelling and the workload on a failing heart.

Scientific Breakdown

What is happening at the cellular level?

Spironolactone is an aldosterone receptor antagonist classified under ATC C03DA01.

It competitively inhibits mineralocorticoid receptors in the distal nephron, thereby reducing expression and activity of epithelial sodium channels (ENaC) and Na+/K+ ATPase.

The net result is less sodium reabsorption, less water retention and relative potassium retention.

Receptor Binding And Downstream Effects

What about metabolites and off‑target activity?

Active metabolites such as canrenone sustain spironolactone’s pharmacological effect.

Anti‑androgenic binding at androgen and progesterone receptors explains endocrine adverse events like gynecomastia and menstrual disturbances.

Renal And Endocrine Consequences

Which physiologic changes require monitoring?

Potassium retention creates hyperkalaemia risk, especially when combined with ACE inhibitors or ARBs.

Anti‑androgenic activity provides off‑label benefit in acne and hirsutism but may cause sexual dysfunction in men and menstrual changes in women.

Higher doses, for example above 100 mg/day, increase endocrine adverse effects and raise potassium risk.

Scope Of Approved & Off‑Label Use

United Kingdom Approvals

What is spironolactone authorised for?

Regulatory approvals in major jurisdictions list indications including hypertension, heart failure, oedema due to cirrhosis or nephrotic syndrome, primary hyperaldosteronism and hypokalaemia.

In the UK context, spironolactone is used as a prescription medicine in cardiology, nephrology and endocrinology clinics.

Tablet strengths in the market include 25 mg, 50 mg and 100 mg and oral suspension options exist for patients who require them.

Notable Off‑Label Trends

How do clinicians use spironolactone beyond licensed indications?

Off‑label prescribing is common for hormonal acne and hirsutism in women, typically at 50–200 mg/day depending on response.

Use in primary aldosteronism work‑ups is frequent as a therapeutic and diagnostic adjunct in specialist settings.

Dermatology prescribing among younger women has grown, which has prompted safety pathways for contraception and pregnancy testing before and during treatment.

Dosage Strategy

General Dosing

What is the general approach to starting spironolactone?

Start low and titrate according to clinical response and laboratory monitoring.

Standard strengths are 25 mg, 50 mg and 100 mg tablets and an oral suspension at 25 mg/5 ml supports paediatric or swallowing‑impaired patients.

Baseline renal function and electrolytes should guide dosing decisions.

Condition‑Specific Dosing

How does dose vary by condition?

Heart failure: initiate at 25–50 mg once daily, with maintenance often 25–50 mg and escalation up to 200 mg/day in refractory situations.

Resistant hypertension: typical range 50–100 mg/day titrated to effect, with a maximum of 200 mg/day if clinically justified.

Oedema in cirrhosis or nephrotic syndrome: many regimens start near 100 mg/day in divided doses with a total range of 25–200 mg/day.

Primary aldosteronism often requires higher doses, commonly 100–400 mg/day to control biochemical abnormalities.

Elderly patients should start at the lowest effective dose with close monitoring.

Renal impairment: avoid if eGFR below 30 mL/min and reduce dose if there is mild to moderate impairment.

For acne and hirsutism, dermatology regimens usually sit at 50–200 mg/day with contraception counselling.

Monitoring schedule: baseline electrolytes and renal function, recheck within 3–7 days of starting or after dose changes, then again at one month and periodically thereafter.

Safety Protocols

Contraindications

Who should not receive spironolactone?

Absolute contraindications include acute renal insufficiency, anuria, hyperkalaemia, Addison’s disease and known hypersensitivity to spironolactone.

Relative precautions include mild to moderate renal impairment, advanced liver disease, diabetes and concurrent use of other potassium‑sparing medicines or ACE inhibitors/ARBs.

Adverse Effects

What adverse effects should clinicians warn about?

Common events are hyperkalaemia, gynecomastia in men, menstrual irregularities in women and gastrointestinal upset such as nausea or diarrhoea.

Other reported problems include drowsiness, headache, rash, impotence, leg cramps and rises in creatinine.

Monitoring protocol for UK prescribers: obtain baseline creatinine/eGFR and serum potassium before initiation, repeat within 3–7 days after starting or dose escalation, check at one month, then at intervals tailored to the patient’s renal function and comorbidity profile.

Patients must be counselled to avoid potassium supplements and salt substitutes containing potassium and to report any breast changes or sexual dysfunction promptly.

In overdose, management is supportive with electrolyte monitoring and ECG surveillance; dialysis is generally unhelpful.

Interaction Mapping

Food Interactions

Are there foods to avoid while taking spironolactone?

There are no major food‑drug interactions that require avoidance of normal meals.

Patients should be specifically advised against potassium‑rich supplements and potassium‑containing salt substitutes because of the hyperkalaemia risk.

Drug Combinations To Avoid

Which medicines cause concern when combined with spironolactone?

Monitor closely when spironolactone is used with ACE inhibitors, ARBs, direct renin inhibitors, other potassium‑sparing diuretics (amiloride, triamterene) and high‑dose potassium supplements.

NSAIDs may reduce renal perfusion and exacerbate hyperkalaemia when used concurrently.

Strong CYP inhibitors can alter levels of active metabolites and may affect clinical response.

When endocrine effects are undesirable, eplerenone is an alternative that tends to have fewer anti‑androgenic effects, although cost and availability should be considered.

Check potassium/creatinine within 3–7 days when adding spironolactone to an existing ACE inhibitor or ARB regimen.

Patient Experience Analysis

Survey Data

What do audits and surveys tell us about real‑world benefit?

Cardiology clinic audits and NHS surveys show improved New York Heart Association class and fewer admissions for patients maintained on spironolactone as adjunct therapy.

Dermatology surveys indicate high satisfaction for women with hormonal acne at 50–100 mg/day, balanced by concerns about menstrual changes and the need for pregnancy prevention.

Forum Trends

What are patients saying online?

Many patients describe meaningful symptom benefit such as reduced breathlessness, less oedema and clearer skin within weeks to months depending on indication.

Forum discussions highlight that men frequently report gynecomastia and sexual dysfunction as reasons for stopping therapy.

Female users commonly discuss contraception needs, trial‑and‑error dosing and delays before seeing acne improvement.

Adherence improves when clinicians provide a clear monitoring timetable and written follow‑up instructions.

Distribution & Pricing Landscape

UK Market Dynamics

How widely available is spironolactone in the UK?

Spironolactone is widely available across the UK as generic spironolactone and branded Aldactone with tablet strengths of 25 mg, 50 mg and 100 mg and some suppliers offering oral suspension forms.

Manufacturers noted in supply chains include Pfizer (original Aldactone) and global generics such as Teva, Mylan, Sandoz and Arrow.

NHS formularies commonly favour generic spironolactone for cost‑effectiveness and pharmacy substitution to generics is routine.

International Availability

Is the formulation the same abroad?

International formulations and packaging vary, for example Carospir oral suspension in the US and Espironolactona tablets in Iberia.

Supply chains have been resilient recently with no major shortages reported in the UK, though packaging differences (bottles versus blisters) can affect hospital and community sourcing.

In our online pharmacy, aldactone is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Alternative Options

Comparison Table

Which drugs are most commonly chosen instead of spironolactone?

Eplerenone (Inspra) is a selective mineralocorticoid receptor antagonist with fewer anti‑androgenic effects and a licence for heart failure post‑MI, but it is usually more expensive.

Amiloride and triamterene are potassium‑sparing diuretics that avoid endocrine adverse effects but may be less effective in aldosterone‑mediated disease.

Pros And Cons

How should clinicians weigh choices?

Spironolactone pros include robust evidence in heart failure, proven efficacy in resistant hypertension, low cost and availability in oral suspension form.

Cons include anti‑androgenic side effects such as gynecomastia and menstrual changes, a higher risk of hyperkalaemia in renal impairment and the monitoring burden this entails.

Eplerenone offers fewer hormonal side effects but has cost and availability considerations.

Amiloride and triamterene avoid endocrine effects but may not be suitable for aldosterone‑driven conditions.

Regulatory Status

UK & EU

What is the legal status of spironolactone?

Spironolactone is a prescription‑only medicine in all major regulatory regions listed in the available data.

It is authorised under brands such as Aldactone and as generic spironolactone in Europe and worldwide.

Global Notes

Are there global differences clinicians should note?

The FDA lists indications including hypertension, heart failure, oedema, primary aldosteronism and hypokalaemia, which aligns with EMA approvals under national brands and generics.

Post‑marketing surveillance emphasises reporting of hyperkalaemia and endocrine adverse events.

Consolidated FAQ

Quick Answers Clinicians And Patients Need

Can I take potassium supplements on spironolactone?

No, avoid potassium supplements and potassium‑containing salt substitutes unless a clinician specifically directs and monitors them.

Is a pregnancy test required before starting spironolactone?

Women of childbearing potential should use effective contraception while on therapy and pregnancy avoidance is advised due to animal teratogenicity signals.

How often should bloods be checked?

Check baseline creatinine/eGFR and potassium, recheck within 3–7 days after initiation or dose change, at one month, and then periodically tailored to renal function and concomitant therapies.

When should the drug be stopped?

Stop spironolactone for acute kidney injury, serum potassium rising above thresholds such as 5.5 mmol/L, or intolerable endocrine adverse effects.

How is overdose managed?

Management is supportive with electrolyte monitoring and cardiac observation; dialysis is generally ineffective for spironolactone removal.

Monitoring Checklist

What practical steps should prescribers take?

• Obtain baseline creatinine/eGFR and serum potassium.
• Complete a medication reconciliation to identify interacting drugs such as ACE inhibitors, ARBs, NSAIDs and other potassium‑sparing agents.
• Schedule a blood re‑check within 3–7 days after starting or increasing the dose.
• Arrange follow‑up at one month and then every 3–6 months or sooner if comorbidities evolve.
• Provide written patient information on hyperkalaemia symptoms and contraception counselling where applicable.

Visual Guide

Suggested Infographic Elements

What should a quick infographic include for NHS patients?

Include a simple mechanism snapshot showing aldosterone blockade leading to reduced sodium retention and potassium sparing.

Show a dosage ladder with common starting doses per indication such as heart failure 25–50 mg, resistant hypertension 50–100 mg and oedema 100 mg divided.

Present a monitoring timeline: baseline, 3–7 days, 1 month.

List key warnings such as avoid potassium supplements, report breast changes and contraception for women of childbearing potential.

Patient Leaflet Highlights

What should go into a one‑page leaflet?

Provide a clear list of common side effects including signs of hyperkalaemia, gastrointestinal upset and endocrine changes.

Include storage instructions to keep tablets below 25°C and protect from moisture.

Give missed‑dose guidance: take when remembered unless close to the next dose and do not double up.

Storage & Transport

Recommended Conditions

How should spironolactone be stored?

Store spironolactone below 25°C and protect from moisture and heat in original packaging.

This recommendation applies to tablets and oral suspensions.

Practical Handling For Clinics And Pharmacies

What practical tips improve safety and adherence?

Label dispensed bottles clearly with dosing and monitoring reminders for the patient and their GP.

For oral suspension, supply an accurate measuring device and demonstrate its use where possible.

Expired or unused medication should be returned to pharmacies for safe disposal under UK regulations.

Guidelines For Proper Use

Stepwise Initiation Protocol

What is a practical UK‑centric initiation protocol?

Confirm the indication and check for absolute contraindications such as acute renal failure or hyperkalaemia.

Obtain baseline blood tests including creatinine/eGFR and serum potassium and perform a pregnancy test where relevant.

Start with the lowest effective dose for the indication and document a clear monitoring plan in the notes and on the patient’s medicines list.

Recheck electrolytes within 3–7 days of starting or after a dose change, and adjust dose or stop therapy if potassium rises or renal function worsens.

Long‑Term Follow‑Up

How should ongoing care be organised?

Review patients at one month and then every 3–6 months, or sooner if clinical status or comedications change.

Monitor for endocrine adverse events and reiterate potassium avoidance and contraception advice for women.

If persistent hyperkalaemia risk exists, consider alternatives such as eplerenone or amiloride, or obtain nephrology input.

Document the reason for prescribing and record that the patient has been counselled on potential side effects.

Delivery Across United Kingdom

Final Practical Notes For Clinicians

Which quick reminders help daily practice?

Record baseline potassium and renal function and reconcile medicines before prescribing.

Inform patients about the symptoms of hyperkalaemia such as palpitations, muscle weakness and paraesthesia and tell them to seek urgent review if these occur.

Discuss contraception with women of childbearing potential and ensure a safety plan is in place before starting therapy for acne or other off‑label indications.

When endocrine effects emerge in men, consider switching to eplerenone or discussing dose reduction depending on indication and severity.

Where To Find Spironolactone (Aldactone)

How can patients obtain their medicine safely?

Spironolactone is supplied by major manufacturers including Pfizer for Aldactone and by global generics manufacturers such as Teva, Mylan, Sandoz and Arrow.

Community pharmacies and NHS hospital pharmacies dispense generic spironolactone routinely on prescription.

Some online pharmacies advertise supply options; check registration and follow clinic monitoring plans if ordering remotely.

Quick Reference

Key facts to remember at a glance:

• INN: spironolactone; ATC: C03DA01.
• Available as 25 mg, 50 mg, 100 mg tablets and 25 mg/5 ml oral suspension.
• Indications include heart failure, resistant hypertension and oedema syndromes; off‑label use in hormonal acne is common.
• Avoid if eGFR <30 mL/min and do baseline and early potassium/creatinine monitoring.
• Watch for gynecomastia and menstrual changes; consider eplerenone when hormonal effects are problematic.

References And Evidence Base

Which sources underpin these recommendations?

Information in this guide is drawn from regulatory product information, recent randomised trials and pooled analyses summarised for UK practice and from manufacturers’ data regarding formulations and strengths.

Clinicians should consult local formulary advice and specialist guidance when managing complex cases such as primary aldosteronism or recurrent hyperkalaemia.